Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

Area of Science:

• Hepatology
• Pharmacology
• Infectious Diseases

Background:

• Direct-acting antiviral (DAA) agents have transformed hepatitis C virus (HCV) treatment, enabling interferon-free regimens.
• While effective, DAA combinations present potential drug-drug interactions (DDIs) that require careful management.
• Clinical evaluation of all possible DDI permutations is not feasible, necessitating practical guidance for healthcare providers.

Purpose of the Study:

• To evaluate the drug-drug interaction (DDI) potential of the ombitasvir, paritaprevir, ritonavir, and dasabuvir (3D) regimen.
• To develop mechanism-based and drug-specific guidance for managing DDIs with the 3D regimen.
• To assess the compatibility of the 3D regimen with over 200 commonly prescribed drugs.

Main Methods:

• Systematic review of DDI studies involving the 3D regimen and over 200 drugs from 19 therapeutic classes.
• Comparison of DDI outcomes with the metabolism and elimination pathways of concomitant medications.
• Development of drug-specific guidance based on interaction mechanisms.

Main Results:

• The 3D regimen demonstrated compatibility with numerous drugs frequently prescribed to HCV patients.
• Potential interactions were identified for specific concomitant medications.
• Mechanism-based analysis provided insights into managing identified DDIs.

Conclusions:

• The 3D regimen is generally compatible with many co-prescribed medications for hepatitis C treatment.
• Healthcare providers can mitigate DDI risks by careful medication review, dose adjustment, and patient monitoring.
• This review offers valuable guidance for optimizing the safety and efficacy of the 3D regimen in clinical practice.